Zogenix Adds Debt

Zogenix Inc., a San Diego-based drug company focused on pain management and CNS disorders, has secured an $18 million secured loan facility from Oxford Finance Corp. and CIT Healthcare. The company is currently in registration for an $86.25 million IPO, and has raised $78 million in VC funding from Domain Associates (23.2% pre-IPO stake), Clarus Ventures (23.1%), Scale Venture Partners (15.4%), Thomas McNerney & Partners (13.2%) and Abingworth Ventures (10%).

PRESS RELEASE

Zogenix, Inc. (“Zogenix”), a privately held, specialty pharmaceutical company, announced today it has closed an $18 million secured loan facility with Oxford Finance Corporation and CIT Healthcare LLC.

Zogenix will use the financing proceeds to continue to prepare for the potential launch of its first product, sumatriptan DosePro